Pharmacists in Bryant, AR Accepting Medicare

29 Pharmacists found. Showing 21 - 29

Brooke Lynn Gipson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3220 N Reynolds Rd, Bryant, AR 72022 Phone: 501-837-9680

Kaitlin Danielle Wood, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3322 Hwy 5 N, Bryant, AR 72019 Phone: 501-847-2880

Dr. Erica Turk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3801 Highway 5 N, Bryant, AR 72022 Phone: 501-847-2880    Fax: 501-847-2881

Paula Middleton Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 Highway 5 N, Bryant, AR 72022 Phone: 501-847-7420

Dr. Robert Maltby, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3801 Highway 5 N, Bryant, AR 72022 Phone: 501-847-2880

Dr. Kenna Cassat, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Bryant Ave, Bryant, AR 72022 Phone: 501-847-4615    Fax: 501-847-7693

Cullen Anson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 Highway 5 N, Bryant, AR 72022 Phone: 501-847-7420    Fax: 501-847-5436

Kaleigh Angleton Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 Ar-5, Bryant, AR 72022 Phone: 501-847-7420

Dr. Sara Schaffhauser, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3220 N Reynolds Rd, Bryant, AR 72022 Phone: 501-847-0803    Fax: 501-588-2150

News Archive

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

Quality of patient care does not improve after physician-hospital integration

In an age of increased integration between physicians and hospitals, regulators should continue to scrutinize proposed hospital mergers and take steps to maintain competition, according to a new paper by experts at Rice University's Baker Institute for Public Policy.

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.

Cellectricon to discuss phenotypic assay designs for chronic pain research in webinar

Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join the webinar entitled "Phenotypic Screening Strategies for Chronic Pain Research", taking place on 5 September, 11:00 am to 12:00pm EDT.

Read more Medical News

› Verified 7 days ago

• 1
• 2(current)